Management of venous thromboembolism in pregnancy.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
Mar 2022
Historique:
received: 25 10 2021
revised: 17 01 2022
accepted: 02 02 2022
pubmed: 13 2 2022
medline: 1 4 2022
entrez: 12 2 2022
Statut: ppublish

Résumé

Venous thromboembolism (VTE) in pregnancy, consisting of deep venous thrombosis (DVT) and pulmonary embolism (PE), is a major factor of maternal mortality. Several patient-specific risk factors along with the physiologic changes of pregnancy promote a state of hypercoagulability in pregnant women. Detailed assessment of all pregnant women can establish a risk profile that would guide clinical decisions, and balance potential therapeutic benefits with side effects. Differentiating between physiologic changes of pregnancy and symptoms of VTE can be challenging and warrants meticulous clinical evaluation. Timely and accurate diagnosis of VTE with proper imaging is essential for its management, and systemic anticoagulation remains the cornerstone of VTE prevention and therapy. Furthermore, advanced invasive treatment options such as inferior vena cava filters and thrombectomy can be considered for complex cases. Importantly, the risk of systemic anticoagulation should be balanced against the risk of VTE-associated morbidity and mortality for mother and fetus, and an informed decision should be made. In this review, we present an up-to-date overview of VTE management in pregnancy and the postpartum period.

Identifiants

pubmed: 35149395
pii: S0049-3848(22)00040-8
doi: 10.1016/j.thromres.2022.02.002
pii:
doi:

Substances chimiques

Anticoagulants 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

106-113

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

Auteurs

Dimitrios Rafail Kalaitzopoulos (DR)

Department of Obstetrics, Zurich University Hospital, Zurich, Switzerland. Electronic address: dimkal1991@windowslive.com.

Anastasios Panagopoulos (A)

Cardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, USA.

Saurabhi Samant (S)

Cardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, USA.

Natasha Ghalib (N)

Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.

Jona Kadillari (J)

Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Angelos Daniilidis (A)

Second Department of Obstetrics and Gynaecology, Faculty of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Nicolas Samartzis (N)

Department of Obstetrics and Gynecology, Cantonal Hospital of Schaffhausen, Switzerland.

Janaki Makadia (J)

Cardiovascular Biology and Biomechanics Laboratory, Cardiovascular Division, University of Nebraska Medical Center, Nebraska Medical Center, Omaha, USA.

Leonidas Palaiodimos (L)

Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.

Damianos G Kokkinidis (DG)

Section of Cardiovascular Medicine, Yale University School of Medicine/Yale New Haven Hospital, New Haven, CT, USA.

Nikolaos Spyrou (N)

Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH